This site is intended for US healthcare professionals

This site is intended for US healthcare professionals

Partner with us

The details matter

NUFYMCO is an FDA-approved
interchangeable biosimilar to LUCENTIS®1,3

When it comes to
biosimilars, your choice of
partner can matter as much
as your choice of product When it comes to biosimilars, your choice of partner can matter as much as your choice of product

  • Backed by Zydus USA, one of the US’s leading generics players

  • Delivering quality manufacturing and stability of supply through established, reputable European partners

  • Supporting practices in the integration of biosimilars and providing patient support through ZySupport

LUCENTIS® is a registered trademark of Genentech, Inc.

Not actual patients

NUFYMCO was demonstrated to be clinically equivalent to LUCENTIS®  (ranibizumab injection) in terms of efficacy and safety.5

See Clinical Study

Q Code:
Q5168

NUFYMCO™ (ranibizumab-leyk) has the same attributes as LUCENTIS® (ranibizumab injection)1,2,6

Same FDA-approved indications:

  • wAMD
  • RVO
  • DME
  • DR
  • mCNV

Same dosage strengths:

  • 0.3 mg
  • 0.5 mg

Same formulation and excipients

Same amino acid sequence

Partner with us

Connect with a Zydus Representative

IMPORTANT SAFETY INFORMATION AND INDICATIONS

CONTRAINDICATIONS

NUFYMCO is contraindicated in patients with:

  • Ocular or periocular infections
  • Known hypersensitivity to ranibizumab products or any of the excipients in NUFYMCO. Hypersensitivity reactions may manifest as severe intraocular inflammation.

WARNINGS AND PRECAUTIONS

Endophthalmitis and Retinal Detachments

Intravitreal injections, including those with ranibizumab products, have been associated with endophthalmitis and retinal detachments. Proper aseptic injection technique should always be used when administering NUFYMCO. In addition, patients should be monitored following the injection to permit early treatment should an infection occur.

Increases in Intraocular Pressure

Increases in intraocular pressure have been noted both pre-injection and post-injection (at 60 minutes) while being treated with ranibizumab products. Monitor intraocular pressure prior to and following intravitreal injection with NUFYMCO and manage appropriately.

Thromboembolic Events

Although there was a low rate of arterial thromboembolic events (ATEs) observed in the ranibizumab clinical trials, there is a potential risk of ATEs following intravitreal use of VEGF inhibitors. ATEs are defined as nonfatal stroke, nonfatal myocardial infarction, or vascular death (including deaths of unknown cause).

Neovascular (Wet) Age-Related Macular Degeneration

The ATE rate in the three controlled neovascular AMD studies (AMD-1, AMD-2, AMD-3) during the first year was 1.9% (17 of 874) in the combined group of patients treated with 0.3 mg or 0.5 mg ranibizumab compared with 1.1% (5 of 441) in patients from the control arms. In the second year of Studies AMD-1 and AMD-2, the ATE rate was 2.6% (19 of 721) in the combined group of ranibizumab-treated patients compared with 2.9% (10 of 344) in patients from the control arms. In Study AMD-4, the ATE rates observed in the 0.5 mg arms during the first and second year were similar to rates observed in Studies AMD-1, AMD-2, and AMD-3.
In a pooled analysis of 2-year controlled studies [AMD-1, AMD-2, and a study of ranibizumab used adjunctively with verteporfin photodynamic therapy (PDT)], the stroke rate (including both ischemic and hemorrhagic stroke) was 2.7% (13 of 484) in patients treated with 0.5 mg ranibizumab compared to 1.1% (5 of 435) in patients in the control arms [odds ratio 2.2 (95% confidence interval (0.8-7.1)].

Macular Edema Following Retinal Vein Occlusion

The ATE rate in the two controlled RVO studies during the first 6 months was 0.8% in both the ranibizumab and control arms of the studies (4 of 525 in the combined group of patients treated with 0.3 mg or 0.5 mg ranibizumab and 2 of 260 in the control arms). The stroke rate was 0.2% (1 of 525) in the combined group of ranibizumab-treated patients compared to 0.4% (1 of 260) in the control arms.

Diabetic Macular Edema and Diabetic Retinopathy

In a pooled analysis of Studies D-1 and D-2, the ATE rate at 2 years was 7.2% (18 of 250) with 0.5 mg ranibizumab, 5.6% (14 of 250) with 0.3 mg ranibizumab, and 5.2% (13 of 250) with control. The stroke rate at 2 years was 3.2% (8 of 250) with 0.5 mg ranibizumab, 1.2% (3 of 250) with 0.3 mg ranibizumab, and 1.6% (4 of 250) with control. At 3 years, the ATE rate was 10.4% (26 of 249) with 0.5 mg ranibizumab and 10.8% (27 of 250) with 0.3 mg ranibizumab; the stroke rate was 4.8% (12 of 249) with 0.5 mg ranibizumab and 2.0% (5 of 250) with 0.3 mg ranibizumab.

Fatal Events in Patients with DME and DR at Baseline

A pooled analysis of Studies D-1 and D-2 showed that fatalities in the first 2 years occurred in 4.4% (11 of 250) of patients treated with 0.5 mg ranibizumab, in 2.8% (7 of 250) of patients treated with 0.3 mg ranibizumab, and in 1.2% (3 of 250) of control patients. Over 3 years, fatalities occurred in 6.4% (16 of 249) of patients treated with 0.5 mg ranibizumab and in 4.4% (11 of 250) of patients treated with 0.3 mg ranibizumab. Although the rate of fatal events was low and included causes of death typical of patients with advanced diabetic complications, a potential relationship between these events and intravitreal use of VEGF inhibitors cannot be excluded.

Retinal Vasculitis with or without Occlusion

Retinal vasculitis with or without occlusion, typically in the presence of preexisting intraocular inflammation or post-treatment with other intravitreal agents, have been reported with the use of ranibizumab products. Discontinue treatment with NUFYMCO in patients who develop these events. Patients should be instructed to report any change in vision without delay.

ADVERSE REACTIONS

Injection Procedure

Serious adverse reactions related to the injection procedure have occurred in <0.1% of intravitreal injections, including endophthalmitis, rhegmatogenous retinal detachment, and iatrogenic traumatic cataract.

Clinical Trials Experience

In clinical trials, the most common ocular adverse reactions included conjunctival hemorrhage, eye pain, vitreous floaters, and increased intraocular pressure. The most common non-ocular side effects included nasopharyngitis, anemia, nausea, and cough.

Immunogenicity

As with all therapeutic proteins, there is the potential for an immune response in patients treated with ranibizumab products. The pre-treatment incidence of immunoreactivity to ranibizumab was 0%-5% across treatment groups. After monthly dosing with ranibizumab for 6 to 24 months, antibodies to ranibizumab were detected in approximately 1%-9% of patients. The clinical significance of immunoreactivity to ranibizumab products is unclear at this time.

Postmarketing Experience

The following adverse reaction has been identified during post-approval use of ranibizumab products. Because this reaction was reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate the frequency or establish a causal relationship to drug exposure.

  • Ocular: Tear of retinal pigment epithelium among patients with neovascular AMD

INDICATIONS AND USAGE

NUFYMCO, a vascular endothelial growth factor (VEGF) inhibitor, is indicated for the treatment of patients with:

  • Neovascular (Wet) Age-Related Macular Degeneration (AMD)
  • Macular Edema Following Retinal Vein Occlusion (RVO)
  • Diabetic Macular Edema (DME)
  • Diabetic Retinopathy (DR)
  • Myopic Choroidal Neovascularization (mCNV)

To report SUSPECTED ADVERSE REACTIONS, contact Zydus Pharmaceuticals (USA) Inc. at 1-877-993-8779 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

Please see full Prescribing Information for NUFYMCO.

References

  1. NUFYMCOTM (ranibizumab-leyk) Prescribing Information. Zydus Pharmaceuticals (USA) Inc.; revised June 2026.
  2. LUCENTIS® (ranibizumab injection) [prescribing information]. Genentech, Inc.; revised February 2024.
  3. U.S. Food and Drug Administration. Purple Book: Database of Licensed Biological Products. Accessed August 13, 2026. https://purplebooksearch.fda.gov/index.cfm?blaNo=761473&event=productdetails
  4. U.S. Food and Drug Administration. Considerations in Demonstrating Interchangeability With a Reference Product: Guidance for Industry. Published May 2019. Accessed August 13, 2026. https://www.fda.gov/media/124907/download
  5. Holz FG, Oleksy P, Ricci F, et al; for the COLUMBUS-AMD Study Group. Efficacy and safety of biosimilar FYB201 compared with ranibizumab in neovascular age-related macular degeneration. Ophthalmology. 2022;129(1):54-63. doi:10.1016/j.ophtha.2021.04.031.
  6. Data on File. Zydus Pharmaceuticals (USA) Inc.
  7. Centers for Medicare & Medicaid Services. July 2026 Alpha-Numeric HCPCS File. Updated June 17, 2026. Accessed August 13, 2026. https://www.cms.gov/medicare/coding-billing/healthcare-common-procedure-system/quarterly-update

You are now leaving the Nufymco website

You are being directed to a third-party website. Zydus does not control or endorse the content of the third-party website and is not responsible for its content.

Efficacy and Safety of Biosimilar FYB201 Compared with Ranibizumab in Neovascular Age-Related Macular Degeneration

Frank G. Holz, MD, Piotr Oleksy, MD, Federico Ricci, MD, Joachim Kiefer, PhD, Steffen Schmitz-Valckenberg, MD
American Academy of Ophthalmology. January 2022

Ok